



[Home](#) / [Investors](#) / [News Releases](#)

Insmmed to Participate on Phase III and Beyond Panel at 2011 RBC Capital Markets Healthcare Conference

RICHMOND, Va., Feb. 24, 2011 /PRNewswire/ -- Insmmed Incorporated (Nasdaq: INSM), a biopharmaceutical company, announced today that Timothy Whitten, President & CEO of Insmmed, will participate on the Phase III and Beyond panel as part of the 2011 RBC Capital Markets Healthcare Conference, which will be held at the New York Palace Hotel in New York City, from Wednesday, March 2nd, through Thursday, March 3rd.

The panel will be held at 9:00 AM ET on Thursday, March 3rd, and there will be a live audio webcast available at <http://www.wsw.com/webcast/rbc129/rbc129.panel7>. The webcast will also be archived for 30 days.

About Insmmed

Insmmed Incorporated is a biopharmaceutical company focused on the development of innovative inhaled pharmaceuticals for the site-specific treatment of serious lung diseases, and has a proprietary protein platform aimed at niche markets with unmet medical need. Insmmed's primary focus is on the development of inhaled antibiotic therapy delivered via proprietary advanced pulmonary liposome technology in areas of high unmet need in lung diseases. For more information, please visit <http://www.insmed.com>.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to the results of clinical trials, the development of our products, or the business strategies, plans and objectives of management, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, we may be unsuccessful in developing our product candidates, our expenses may be higher than anticipated and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2009 and Quarterly Report on Form 10-Q for the fiscal quarters ended March 31, 2010, June 30, 2010 and September 30, 2010. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.
